Slingshot members are tracking this event:

PDUFA Date of March 2nd for BMY's Supplemental Biologics License Application (sBLA) for Opdivo in Patients With Locally Advanced Unresectable or Metastatic Urothelial Carcinoma After Platinum-Based Chemotherapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pdufa Date, Supplemental Biologics License Application, Sbla, Locally Advanced, Unresectable, Metastatic, Urothelial Carcinoma, Platinum-based Chemotherapy, Fda